Skip to content
Seerlinq

Clinical evidence

Validated against the gold standard. Studied in routine care.

Seerlinq HeartCore monitors left ventricular filling pressure from a 4-minute fingertip measurement. We validated it against right heart catheterisation, published the results in JACC: Heart Failure, and evaluated it in STOP-DHF, a multicentre study in routine heart failure care.

0.96
ROC AUC against right heart catheterisation
0.88
ROC AUC against echocardiography
330
patients in the STOP-DHF study monitored for 12 months
29
publications and global congress presentations since 2024

*ROC AUC for classifying left ventricular filling pressure as elevated or not elevated. Source: Böhm et al., JACC: Heart Failure, 2026.

Key publications

Key publications and results

HeartCore: filling-pressure monitoring

Journal and yearJACC: Heart Failure · Brief report, 2026 (opens in a new tab)TopicProspective validation, 131 patients with heart failureKey resultROC AUC 0.96 against right heart catheterisation and 0.88 against echocardiography
Journal and yearJACC: Basic to Translational Science · Research letter, 2025 (opens in a new tab)TopicFirst description of the non-invasive system based on PPG signalKey resultFilling pressure estimated from a fingertip PPG signal, with no implant
Journal and yearEuropean Heart Journal · ESC Congress 2025 (opens in a new tab)TopicReal-world study: 176 patients, 3 sites, 3 months of home monitoring every other dayKey result0 cardiac deaths, 0 heart failure hospitalisations, 1.7% overall event rate
Journal and yearEuropean Journal of Heart Failure · Heart Failure 2026 (ESC Heart Failure Congress 2026)TopicSTOP-DHF study: 330 patients, 6 months of home monitoring every other dayKey resultFewer primary endpoint events than a matched benchmark: 4.2% vs 9.0% (p < 0.001; 95% CI 2.3–7.0%)

Research: new applications of PPG

One PPG signal, more patient data

Journal and yearEuropean Heart Journal · ESC Congress 2025 (opens in a new tab)TopicHeart failure screening with a simple pulse oximeter, 386 patientsKey resultc-statistic 0.89 for detecting heart failure
Journal and yearEP Europace · EHRA Congress 2026TopicAtrial fibrillation detection in heart failure telemonitoring, 247 patientsKey resultConsistent accuracy in internal and external validation

Results from screening and atrial fibrillation studies are research findings and are not part of the certified intended use.

The method

Built on the physiology of the preload challenge

HeartCore uses a controlled preload challenge. The patient moves from standing to recumbent position, which changes venous return. When filling pressure is normal, the cardiovascular system adapts to this change efficiently. When it is elevated, that adaptation is impaired, and this produces distinct patterns in the peripheral PPG signal. HeartCore analyses this response and estimate a non-invasive LVFP.

Every recording goes through automatic signal-quality checks. Recordings that do not meet predefined quality criteria are excluded.

Protocol
4 minutes at home, every other day: 2 minutes standing, then 2 minutes lying down, with a Seerlinq pulse oximeter connected to a smartphone. No healthcare professional needs to be present.
Why it matters
Elevated filling pressure is one of the earliest hemodynamic markers of worsening heart failure. In many patients it rises days to weeks before symptoms appear, often up to 4 weeks earlier. That gives the care team time to act. When HeartCore shows filling pressure rising, a clinician can call the patient, check symptoms and medication, and adjust treatment remotely. The goal is to stop the decline early and prevent hospitalisation.
Place in care
HeartCore does not replace echocardiography. It complements standard care with frequent measurements at home, between clinic visits.
  1. 2 minStanding
  2. 2 minLying down
Measurement protocol: 2 minutes standing, then 2 minutes lying down

Validation

Tested against invasive and non-invasive references

In a prospective validation study of 131 patients with heart failure, Seerlinq LVFP was compared with right heart catheterisation, the invasive gold standard, and with echocardiography. The results were published in JACC: Heart Failure in 2026.

The study included all heart failure phenotypes (HFpEF, HFmrEF and HFrEF). More than half of the patients had atrial fibrillation or flutter, a common challenge for PPG-based methods. Seerlinq LVFP also responded to treatment, changing significantly within 2 days of an increase in loop-diuretic dose.

Patient selection

Which patients benefit most

Most suitable

  • Patients recently hospitalised for heart failure
  • NYHA class II–III
  • Patients at high risk of decompensation
  • Patients undergoing optimisation of guideline-directed medical therapy
  • Patients with HFpEF, who are often underserved by existing monitoring options

Less suitable

  • Patients in chronic NYHA class IV
  • Patients with advanced chronic kidney disease (GFR < 25 ml/min) who do not respond to diuretics, and patients on chronic dialysis
  • Patients who are immobile long term, or cannot change position between standing and lying down

The system was designed for older patients, including those with limited digital experience, and needs minimal training.

Clinical study

STOP-DHF: hemodynamic-guided care in routine practice

STOP-DHF (A Non-Invasive Hemodynamic-Guided Strategy to Prevent Heart Failure Decompensation) studies HeartCore-guided care in patients treated in everyday cardiology practice.

Study facts

  • Prospective, multicentre, single-arm study in routine care
  • 330 patients with heart failure, NYHA class II–III, at 99 sites
  • Presented at THT 2026 (Boston) and ESC Heart Failure 2026 (ESC-HF)
STOP-DHF at THT 2026 (opens in a new tab)

Preliminary result

At 6 months, primary endpoint events occurred in 4.2% of patients, compared with 9.0% in a matched benchmark (p < 0.001; 95% CI 2.3–7.0%).

Preliminary results from a single-arm study, compared with a matched benchmark rather than a randomised control group. Twelve-month results will follow.

Research partnerships

Research with leading institutions

We work with clinicians and researchers at leading institutions in Europe and Israel.

Patients

In their words

“Five minutes every morning, and my doctors are watching. It kept me out of hospital.”

Roman Šelemba, 61

Publications

All publications and presentations

29 publications and global congress presentations since 2024.

Peer reviewed

Congress presentations

See the data in your own practice

Want to see how it works in your clinic? Talk to us about a pilot.

Talk to our team